Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants

In a phase 1 dose-escalation trial at 2 dosing levels, we assessed the safety of intratracheal administration of a single-dose of human umbilical cord blood-derived mesenchymal stromal cells in 12 extremely low birth weight infants <28 weeks of gestation and <1000 g at birth at 5-14 days of life. The treatment was well tolerated and appears to be safe and feasible, and warrants a larger randomized-controlled blinded study. Trial registration ClinicalTrials.gov: NCT02381366. In a phase 1 dose-escalation trial at 2 dosing levels, we assessed the safety of intratracheal administration of a single-dose of human umbilical cord blood-derived mesenchymal stromal cells in 12 extremely low birth weight infants <28 weeks of gestation and <1000 g at birth at 5-14 days of life. The treatment was well tolerated and appears to be safe and feasible, and warrants a larger randomized-controlled blinded study. ClinicalTrials.gov: NCT02381366. So You Want to Give Stem Cells to Babies? Neonatologists and Parents’ Views to Optimize Clinical TrialsThe Journal of PediatricsVol. 210PreviewTo identify barriers and enablers that may influence parents' and neonatologists’ participation in clinical trials of mesenchymal stromal cells for bronchopulmonary dysplasia. Full-Text PDF Stem cells for bronchopulmonary dysplasia: A promising yet challenging journey lies aheadThe Journal of PediatricsVol. 212PreviewWe congratulate the authors for their commendable effort in conducting a phase I clinical trial on stem cell in prevention of bronchopulmonary dysplasia (BPD).1 With increased survival of extremely low birth weight infants, BPD has emerged as a major morbidity in this population.2 Regenerative medicine in the form of stem cell therapy seems to be a promising solution for healing the affected lungs in this population. Full-Text PDF